15 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
1 May 18
Cocrystal Pharma, Inc., Prices $8,000,000 Common Stock Offering
8:35am
), (“Cocrystal” or the “Company”) a clinical stage biotechnology company focused on developing innovative antiviral therapeutics, today announced
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
7 Jan 19
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
9:03am
and our innovative platform will enable us to rapidly advance important new treatments for influenza, which is a significant worldwide unmet need
8-K
COCP
Cocrystal Pharma Inc
7 Jul 11
Acquires Biozone Laboratories, Inc. and Related Companies
12:00am
sponsors to develop innovative medicines using currently available products. According to Section 505(b)(2) guidelines, an NDA approval can be obtained … develop and commercialize additional OTC and generic prescription drugs and/or innovative pharmaceuticals.
We develop and manufacture OTC drugs and intend
S-1
COCP
Cocrystal Pharma Inc
21 Sep 11
IPO registration
12:00am
sponsors to develop innovative medicines using currently available products. According to Section 505(b)(2) guidelines, an NDA approval can be obtained … and/or innovative pharmaceuticals.
We develop and manufacture OTC drugs and intend to develop generic branded pharmaceuticals. All pharmaceutical products must meet
8-K
COCP
Cocrystal Pharma Inc
19 May 11
Completion of Acquisition or Disposition of Assets
12:00am
OTC and generic prescription drugs and/or innovative pharmaceuticals.
We manufacture OTC drugs through third party service providers. All … clinical trials in the case of topical products. The development and commercialization process, particularly with respect to innovative products, is both
CORRESP
gjewwu49
19 Dec 11
Correspondence with SEC
12:00am
- Prev
- 1
- Next